WRITTEN ANSWERS TO QUESTIONS

Schemes submitted by the West Bengal Government for approval

*144. SHRI DEBABRATA BISWAS : Will the MINISTER OF PLANNING AND PROGRAMME IMPLEMENTATION be pleased to state :

(a) The details of the schemes submitted by the West Bengal Government to the Planning Commission for approval; and

(b) by when the schemes are proposed to be cleared ?

THE MINISTER OF STATE OF THE MINISTRY OF PLANNING AND PROGRAMME IMPLEMENTARY AND THE MINISTER OF STATE IN THE MINISTRY OF NON-CONVENTIONAL ENERGY SOURCES (SHRI SUKH RAM) : (a) and (b) No Scheme/Project submitted by West Bengal Government for investment approval is pending in Planning Commission.

Investment and Production by Foreign Drug Companies

*147. SHRIMATI KAILASHPATI :
SHRI RAJNI RANJAN SAHU :

Will the PRIME MINISTER be pleased to state :

(a) what are the names of drug companies operating in India which have more than 26 per cent foreign equity;

(b) whether it is a fact that none of these companies has made any new investment despite the fact that the profitability has gone up;

(c) whether it is also a fact that production of bulk drugs of these companies has declined and imports have gone up during this period;

(d) if so, what was the production of each drug of each company and imports during this period, yearwise; and

(e) what was the equity capital and reserves during 1990-91 and 1991-92 of each company ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The names of drug companies having foreign equity of more than 26%, operating in India, are given at Statement-I. (*See below*).

(b) The position for the period between 1990 and 1992 has been examined for this purpose. As per the available information, profitability of the companies has increased only marginally or has decreased, and in this period, industrial licences to the tune of about Rs. 37 crores and letters of intent/registrations with investment indications of about Rs. 67 crores have been given to these companies.

(c) and (d) Companywise production of all drugs is not being monitored in this Department. However, production of monitored bulk drugs by these companies, to the extent available, is given at Statement-II, which shows that while there is a decline in production of some companies in respect of a few drugs, the production of other drugs has increased. (*See below*) Companywise imports of individual bulk drugs are not being monitored.

(e) Information to the extent available is given at Statement-III.

Statement-I

LIST OF COMPANIES WITH FOREIGN EQUITY OVER 26%

S. No.	Name of the Company	Percentage of foreign equity
1.	M/s. Johnson & Johnson Ltd.	76.00%
2.	M/s. Roche Products	74.00%
3.	M/s. Bayer India Limited	51.00%
4.	M/s. Proctor & Gamble (Richardson Hindustan)	51.00%
5.	M/s. Sandoz (I) Limited	50.94%
6.	M/s. Alkali & Chemicals (Amalgamated in ICI)	50.83%
7.	M/s. Abbott Laboratories	40.00%
8.	M/s. CIBATUL	30.00%
9.	M/s. Boots Pharmaceuticals Limited	40.00%
10.	M/s. Burroughs Wellcome	40.30%
11.	M/s. Carter Wallace	40.00%
12.	M/s. Eskayef Limited	40.00%
13.	M/s. C.E. Fulford	40.00%
14.	M/s. Geoffrey Manners	40.00%
15.	M/s. Glaxo India Limited	40.00%
16.	M/s. Griffen Labs.	40.00%
17.	M/s. Hindustan Ciba-Geigy of India Ltd.	40.00%
18.	M/s. Hoechst Pharmaceuticals	40.00%
19.	M/s. Infer India Limited	40.00%
20.	M/s. E. Merck (I) Limited	40.00%
21.	M/s. Modi Mundi Pharma	40.00%
22.	M/s. Parke Davis Limited	40.00%
23.	M/s. Pfizer Limited	40.00%
24.	M/s. Rhone-Poulene (May & Baker)	40.00%
25.	M/s. Synbiotics	40.00%
26.	M/s. Wander	40.00%
27.	M/s. Wyeth Labs.	40.00%
28.	M/s. Beecham (HMN)	39.999%
29.	M/s. Cynamid India Limited	38.99%
30.	M/s. Uni-Sankyo	32.99%
31.	M/s. German Remedies	39.95%
32.	M/s. Reekitt Colman	39.95%
33.	M/s. Uni-UCB	39.91%
34.	M/s. Duphar Interfran Limited	39.00%
35.	M/s. Searle (I)	39.00%
36.	M/s. Boebringer—Mannheim India Limited	38.40%
37.	M/s. G.T.B.L.	34.20%
38.	M/s. Roussel	33.33%
39.	M/s. Rallis	29.80%

Statement-II]

The production of the monitored Bulk drugs during 1990-91 & 1991-92 *by companies having foreign equity more than* 26% *operating in India.*

Name of the Co./Bulk drugs	A/c Unit	Production during	
		1990-91	1991-92
1	2	3	4
1. *M/s. Abbott Labs*			
(i) Erythromycin Stearate IP	T	22.33	18.00*
2. *M/s. Bayer (I) Ltd.*			
(i) Chloroquine Phosphate	T	32.96	30.19
(ii) Mebhydroline	T	21.76*	10.52
3. *M/s. Boehringer-Mannheim*			
(i) Chloramphenicol Powder	T	50.87	66.52
(ii) Glibenclamide	T	0.58	1.23
4. *M/s. Burroughs Wellcome*			
(i) Dapsone	T	4.07	13.30
(ii) DEC Citrate	T	7.82	8.27
(iii) Digoxin	Kg.	16.00	13.58
(iv) Pyrimethamine	T	NIL	NIL
(v) Isoprenaline	Kg.	5.00	15.00
(vi) Trimethoprim	T	70.89	97.02
5. *M/s. Boots Company*			
(i) Ibuprofen	T	178.60	167.77
(ii) Diloxanide Furoate	T	NIL	NIL
(iii) Crystalline Insulin	MU	2703.00	3097.00
6. *M/s. Cynamid*			
(i) Tetracycline	T	NIL	NIL
7. *M/s. Duphar-Interfran Ltd.*			
(i) Cholecalaciferol IP (Vit. D3)	Kg.	461.00	322.60
(ii) Isoxsuprine Hydrochloride	T	1.91	1.55
(iii) Paracetamol	T	NIL	NIL
8. *M/s. Eskayef*			
(i) Trimterene	T	N.A.	0.10
(ii) Trifluperazine	T	0.24	0.10
9. *M/s. E. Merck (India) Ltd.*			
(i) Vitamin E (Acetate)	T	86.26	167.06
(ii) Vitamin P (Rutin)	T	NIL	NIL
(iii) Vitamin K	T	NIL	NIL
(iv) Chloroquine Phosphate	T	57.08	57.26
10. *M/s. German Remedies Ltd.*			
(i) Hydroxyethyl Theophylline	T	70.47	70.76
(ii) Sulfamoxole	T	63.97	49.49
(iii) Theophylline	T	86.96	80.88
(iv) Trimethoprim	T	6.17	7.38
(v) Xantinolnicotinate	T	15.05	13.33
11. *M/s. Geoffrey Manners*			
(i) Aluminium Hydroxide	T	935.85	992.49
(ii) Benzathine Penicillin	MMU	14.27	16.14
12. *M/s. Glaxo India Ltd.*			
(i) Betamethasone	Kg.	1141.00	1190.00
(ii) Griseofulvin	T	NIL	8.65
(iii) Ibuprofen	T	0.25	—
(iv) Ranitidine	T	25.56	19.55
(v) Triple Vaccine	KL	3.84	4.52
(vi) Vitamin A	MMU	13.77	7.33

1	2	3	4
13. *M/s. Hindustan Ciba Geigy*			
(i) Dihydralazine	T	17.30	11.72
(ii) Hydrochlorothiazide	T	12.42	6.50
(iii) Sulphaphenazole	T	2.91	NIL
(iv) Sulphasomidine	T	15.48	2.24
(v) Sulphachlazole	T	2.94	NIL
14. *M/s. Hoechst India Ltd.*			
(i) Baralgan Ketone	T	2.49	2.50
(ii) Frusemide	T	7.80	7.59
(iii) Glybenclamide	T	2.49	2.80
(iv) Isopropyl Antipyrine	T	22.92	22.79
(v) Pheniramine Maleate	T	26.06	38.00
(vi) Procaine	T	36.16	48.41
(vii) Tolbutamide	T	7.90	5.26
15. *M/s. Infar (I) Ltd.*			
(i) Metclopramide	T	0.24*	0.39
16. *M/s. Parke Davis*			
(i) Amodiaquine HCl	T	16.69	3.49
(ii) Chloramphenicol Palmitate	T	11.25	12.87
(iii) Chloramphenicol Powder	T	24.69	17.65
(iv) Diphenhydramine Hcl	T	0.30	0.65
17. *M/s. Pfizer Ltd.*			
(i) Chlorpropamide	T	29.12	44.38
(ii) Isoniazid	T	44.93	24.45
(iii) Oxytetracycline & its salts	T	112.77	107.09
(iv) Pyrental Palmoate	T	16.40	19.84
(v) Sodium Pas	T	NIL	NIL
(vi) Tetracycline	T	N.A.	N.A.
18. *M/s. Proctor & Gamble*			
(i) Menthol	T	28.05	44.09
19. *M/s.Rallis India Ltd.*			
(i) Ibuprofen	T	NIL	NIL
(ii) Iron Dextran	KL	23.55*	22.18
(iii) Laparamide	T	NIL	NIL
20. *M/s. Reckitt & Colman*			
(i) Parachloro Meta Xylenol	T	88.46	110.10
21. *M/s. Rhone Poulene (I) Ltd.*			
(i) Chlorpromazine	T	0.51*	1.62
(ii) Phtholylsulphathiazole	T	NIL	NIL
(iii) Prechlorperazine	T	NIL	NIL
(iv) Sulphadiazine	T	4.07	NIL
(v) Sulphathinzole	T	NIL	NIL
(vi) Sulphadimidine	T	NIL	NIL
(vii) Metronidazole	T	3.18	9.66
22. *M/s. Roche Products*			
(i) Chloradiazepoxide	Kg.	888.00	363.00
(ii) Dehydrometine	Kg.	182.00	104.00
(iii) Diazepam	T	0.66	0.91
(iv) Sulphamethoxazole	T	18.68	32.69
(v) Vitamin A	MMU	60.25	53.05
(vi) Vitamin E	T	7.71	7.14
23. *M/s. Roussel Pharma*			
(i) Framycetin	T	6.36	8.09

1	2	3	4
24. *M/s. Sandoz (I) Ltd.*			
(i) Atropine	Kg	NIL	NIL
(ii) Digaxin	Kg	10.00*	4.27
(iii) Sulphamethoxazole	T	N.A.	N.A.
25. *M/s. Searle (I) Ltd.*			
(i) Diphenoxylate Hydrochloride	T	1.93	1.82
(ii) Spironolactone	T	0.52*	0.26
26. *M/s. UNI Sankyo Ltd.*			
(i) Pyrazinamide	T	1.50	0.45
27. *M/s. UNI-UCB Ltd.*			
(i) DEC Citrate	T	N.A.	N.A.
28. *M/s. Wander Ltd.*			
(i) Sodium Pas	T	31.02	18.59*
29. *M/s. Wyeth Labs.*			
(i) Hydrocortisone	Kg.	15·00	2.00
(ii) Prednisolone	*Kg.*	2246·00	1949·00

*: Estimated.

N.A. : Not available.

Statement-III

Details of Paid up Capital, Reserves and Surpluses of Drug Companies with foreign equity over 26% for the year 1990-92.

(In crores)

Sl. No.	Name of the Company	Paid up Capital	Reserves and Surpluses
1.	M/s. C.E. Fulford (Fulford India Ltd.)	1.60	4.71
2.	M/s. Abbot Laboratories	2.25	3 18
3.	M/s. Geoffery Manners	2·88	8.26
4.	M/s. Parke-Davis Ltd.	12·05	5.71
5.	M/s. Hindustan Ciba-Geigy of India Limited	26.56	48.45
6.	M/s. Infar India Limited	3·80	6.73
7.	M/s. Gujarat Themis Biosyn Ltd.	2.50	0.16
8.	M/s. Glaxo India Ltd.	20·00	61.24
9.	M/s. Hoechst Pharmaceuticals	9.58	106.74
10.	M/s. Burroughs Wellcome	6·00	15.24
11.	M/s. Proctor & Gamble (Richardson Hindustan)	6.68	15.24
12.	M/s. Bayer India Ltd.	16.22	22.40
13.	M/s. Cynamid India Ltd.	5.25	16·09
14.	M/s. Alkali & Chemicals (ICI)	40.87	126.95
15.	M/s. Pfizer Limited	11.72	17.88
16.	M/s. Boots Pharmaceuticals Ltd.	8.10	14.26
17.	M/s. Sandoz (I) Ltd. (31.12-91)	7.95	28.79
18.	M/s. Wyeth Labs.	3.88	5.21
19.	M/s. Roche Products	4·81	6.22
20.	M/s. E. Merck (I) Ltd	5.94	8.53
21.	M/s. Duphar Interfran	1·84	4.97
22.	M/s. German Remedies	6·53	7.58
23.	M/s. Rallis	9.49	36.03
24.	M/s. Reckitt Colman	8.39	23.73
25.	M/s. Beacham (HMM)	14.18	33.79
26.	M/s. Searle (I)	5.22	20.78
27.	M/s. Roussel India Ltd.	6.28	7·59
28	.M/s. Eskayef	7·5	32.59